Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSCs Injections for Chronic Stroke
NCT02813512Phase 1Completed
- Sponsor
- Gwo Xi Stem Cell Applied Technology Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GXNPC1 in ischemic stroke, sponsored by Gwo Xi Stem Cell Applied Technology Co., Ltd. Primary endpoint: Neurological function assessment at 6 months. Started Oct 2017; status: completed.
02
Drugs
GXNPC1
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02813512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813512.